Nearly three-quarters of physicians say prior authorization denials have gotten worse over the past five years — and in oncology specifically, that trend isn't just a billing inconvenience. It's a documented driver of delayed treatment, and in the most severe cases, worse patient outcomes. For oncology practices, prior authorization has quietly become the single biggest bottleneck between a treatment decision and a paid claim.
What the 2026 data actually shows
The American Medical Association's Prior Authorization Physician Survey, released in May 2026, found that 74% of physicians report denials have increased over the last five years, and roughly 6 in 10 are now concerned that payers' growing use of AI in claims adjudication will push denial rates even higher.
That concern is grounded in real numbers. A 2024 KFF analysis of CMS transparency data found insurers denied about 19% of in-network claims and 37% of out-of-network claims, for a combined average denial rate near 20% across all claims. Oncology consistently sits above that baseline — prior authorization requirements for specialty cancer drugs have climbed sharply over the past decade, with PA now required for over 95% of specialty brand-name cancer medications, up from roughly 73% just fifteen years ago.
The downstream effect on patients is the part that should concern every oncology practice leader, not just billing teams. Research published via IQVIA found more than 40% of commercial patients and 53% of Medicare patients never start the oncology treatment their physician originally prescribed after hitting a prior authorization denial or step-therapy requirement. That's not a claims problem — that's a care problem with a claims trigger.
The clinical cost, not just the financial one
It's tempting to treat prior authorization purely as an administrative or revenue issue. The data says that's a mistake. In a survey conducted by the American Society of Clinical Oncology, nearly all responding oncologists reported that a patient in their care had experienced harm connected to prior authorization — 96% reported treatment delays, 93% reported patients being forced into a second-choice therapy, and 36% reported a patient death they connected to the prior authorization process.
Timing matters clinically in a way it doesn't in most other specialties. Research cited in prior authorization literature has linked each week of delay in starting cancer treatment to a 1.2% to 3.2% increased risk of death. In radiation oncology specifically — widely cited as the specialty facing the heaviest PA burden of any medical field — roughly a third of radiation oncologists in an AMA-affiliated survey reported that prior authorization had delayed a patient's treatment by at least a week.
The part practices consistently underuse: appeals
Here's the detail that gets lost in most conversations about oncology PA, and it's the single most actionable finding in the data: initial denials are frequently overturned when appealed — which means many practices are absorbing revenue losses on claims that were winnable.
- A study of imaging orders for cancer surgical planning found 58.2% of initially denied requests were overturned on appeal.
- In gynecologic cancer care, one study found 97.6% of initial denials were appealed, and 79% of those appeals were ultimately approved.
- In radiation oncology, a 2024 study found 61.7% of denials were reversed on appeal.
Put simply: a large share of oncology prior authorization denials aren't final decisions, they're negotiating positions. Practices that treat the first denial as the end of the process are leaving approvable revenue on the table.
What's changing in 2026 — and what isn't
CMS's Interoperability and Prior Authorization Final Rule, taking effect in 2026, requires federally regulated plans (Medicare Advantage, Medicaid managed care, and ACA Marketplace plans) to respond to urgent PA requests within 72 hours and standard requests within 7 calendar days, with an electronic tracking API requirement following in 2027. It's a meaningful step toward transparency — payers are now required to publicly report approval and denial rates for the first time.
But the data those reports produce is aggregated across all services, not broken out by specialty. A payer can report a 95% approval rate overall while approving oncology-specific requests at a much lower rate — the aggregation hides exactly the information oncology practices need most. Practices that want specialty-level visibility into which payers are the highest-friction still have to build that picture themselves, claim by claim.
Where this leaves oncology practices
The pattern in the 2026 data is consistent: prior authorization volume and complexity are rising, payer AI adoption is accelerating denials faster than practices can manually respond, and a meaningful share of those denials are reversible on appeal if practices have the documentation and staff time to pursue them. For independent and small-group oncology practices without a dedicated prior auth team, that combination is exactly where revenue quietly leaks out of the system — not from services that are truly non-covered, but from approvable requests that never get the second look they need.
FAQ
Why is prior authorization especially difficult in oncology?
Oncology treatments are more likely to require prior authorization than almost any other specialty — over 95% of specialty brand-name cancer drugs now require it — and the clinical complexity of chemotherapy, immunotherapy, and radiation regimens makes documentation and payer review more involved than for routine care.
How often are oncology prior authorization denials overturned on appeal?
Studies show overturn rates vary by service type but are often substantial — one study found 58.2% of denied imaging orders for cancer care were overturned on appeal, and a radiation oncology study found 61.7% of denials were reversed. This suggests many initial denials are not final determinations.
How much does prior authorization delay affect cancer treatment outcomes?
Research has associated each week of delay in starting cancer treatment with a 1.2% to 3.2% increased risk of death, making PA-related delays a clinical concern, not just an administrative one.
What is changing about prior authorization requirements in 2026?
CMS's Interoperability and Prior Authorization Final Rule now requires federally regulated payers to respond to urgent requests within 72 hours and standard requests within 7 days, and to publicly report approval/denial metrics — though this data is currently aggregated and not broken out by specialty.
